Scholarlink

Background <p>Obesity is a complex metabolic condition marked by irregular fat deposition, altered lipid profiles, persistent low-grade inflammation, and impaired liver function. Currently available anti-obesity drugs often show limited long-term use due to undesirable side effects. Beauvericin (BEA), a secondary metabolite produced by the Fusarium genus, as well as Beauveria bassiana and certain Isaria species, has attracted attention because of its broad spectrum of biological activities, its reported antioxidant properties, which may have the ability to regulate lipid metabolism.</p> Objective <p>The present study was designed to evaluate the anti-obesity and also showed hepatoprotective effects of BEA in a high-fat diet (HFD)–induced obesity model in Wistar albino rats in the liver profile test.</p> Methods <p>Obesity was induced by feeding rats an HFD for 8 weeks. Animals were divided into five groups: normal control, obese, standard drug, and BEA-treated groups (8 and 10&#xa0;mg/kg). Anthropometric parameters, serum lipid profile, haematological indices, liver function markers, adipokines, and fecal lipid content were assessed.</p> Results <p>While lowering adiponectin levels, HFD feeding markedly increased body weight, food and calorie consumption, BMI, Lee index, serum lipids, inflammatory markers, leptin levels, and hepatic enzymes. Body weight growth and obesity parameters were reduced in a dose-dependent way by BEA treatment, which also improved fecal lipid excretion, altered adipokinin imbalance, stabilized haematological and liver parameters, and improved the lipid profile. The effects of BEA at a higher dose (10&#xa0;mg/kg) were similar to the standard drug.</p> Conclusion <p>Beauvericin shows notable anti-obesity and hepatoprotective effects in HFD-induced obese rats, supporting its potential as a promising therapeutic compound for obesity-associated metabolic disorders.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacological investigation of Beauvericin in high-fat diet-induced obesity in rats

  • 期刊论文

  • 发表日期：

    2026年7月6日

查看全文
  • Anjali Singh,
  • Bhupendra Chauhan,
  • Neelam Sharma,
  • Amarjeet Singh,
  • Deepika Rani,
  • Praveen Kumar

摘要

Background

Obesity is a complex metabolic condition marked by irregular fat deposition, altered lipid profiles, persistent low-grade inflammation, and impaired liver function. Currently available anti-obesity drugs often show limited long-term use due to undesirable side effects. Beauvericin (BEA), a secondary metabolite produced by the Fusarium genus, as well as Beauveria bassiana and certain Isaria species, has attracted attention because of its broad spectrum of biological activities, its reported antioxidant properties, which may have the ability to regulate lipid metabolism.

Objective

The present study was designed to evaluate the anti-obesity and also showed hepatoprotective effects of BEA in a high-fat diet (HFD)–induced obesity model in Wistar albino rats in the liver profile test.

Methods

Obesity was induced by feeding rats an HFD for 8 weeks. Animals were divided into five groups: normal control, obese, standard drug, and BEA-treated groups (8 and 10 mg/kg). Anthropometric parameters, serum lipid profile, haematological indices, liver function markers, adipokines, and fecal lipid content were assessed.

Results

While lowering adiponectin levels, HFD feeding markedly increased body weight, food and calorie consumption, BMI, Lee index, serum lipids, inflammatory markers, leptin levels, and hepatic enzymes. Body weight growth and obesity parameters were reduced in a dose-dependent way by BEA treatment, which also improved fecal lipid excretion, altered adipokinin imbalance, stabilized haematological and liver parameters, and improved the lipid profile. The effects of BEA at a higher dose (10 mg/kg) were similar to the standard drug.

Conclusion

Beauvericin shows notable anti-obesity and hepatoprotective effects in HFD-induced obese rats, supporting its potential as a promising therapeutic compound for obesity-associated metabolic disorders.

Graphical Abstract